Sana生物科技

最新新闻

• 评级变动
  Citi Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/3/5
• 评级变动
  TD Cowen Maintains Sana Biotechnology(SANA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• H.C. Wainwright Remains a Buy on Sana Biotechnology (SANA)
  TipRanks · 2026/9/22
• 评级变动
  Rodman & Renshaw Initiates Sana Biotechnology(SANA.US) With Buy Rating, Announces Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• 公司公告
  Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer Wyrick Susan D.
  SEC · 2026/3/5
• 公司公告
  4: Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bilenker Joshua H.
  SEC · 2026/6/6
• H.C. Wainwright Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)
  TipRanks · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for Sana Biotechnology(SANA.US), With a Forecast Between $7 to $16
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  TD Cowen Maintains Sana Biotechnology(SANA.US) With Buy Rating, Announces Target Price $3.21
  \u5e02\u573a\u8d44\u8baf · 2026/4/14
• 评级变动
  Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Raises Target Price to $7
  \u5e02\u573a\u8d44\u8baf · 2026/4/14
• BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $6
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $3.07
  \u5e02\u573a\u8d44\u8baf · 2026/5/18
• Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 公司公告
  Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer Wyrick Susan D.
  SEC · 2026/3/11
• 公司公告
  Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Rosiello Robert L.
  SEC · 2026/6/6
• 公司公告
  Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer Wyrick Susan D.
  SEC · 2026/3/7
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP)
  TipRanks · 2026/3/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。